Advance drug discovery at scale with AWS and BioNeMo
See how AWS and BioNeMo are advancing drug discovery at scale using accelerated computing and generative AI.
#MakeYourMove
Healthcare and life sciences organizations face unprecedented pressure to unlock new scientific insights while managing research costs and regulatory requirements. The collaboration between Amazon Web Services (AWS) and BioNeMo addresses these critical challenges head-on.
Key points covered:
Accelerated discovery timelines: Reduce drug development cycles by streamlining the process from model optimization to production.
Automated workflow orchestration: AWS HealthOmics, a HIPAA-eligible services, provisions and orchestrates infrastructure components including workflow engines and compute resources.
Innovation at scale: NVIDIA Inference Microservices (NIMs) and AWS HealthOmics brings together AI capabilities to accelerate drug discovery.
Watch the video to see how generative AI can accelerate drug discovery at scale – and imagine what this could mean for your organization.
Related content that may be of interest
Ready to explore how AWS can help your organization?
We can connect you to the right Manufacturing Experts
Gain exclusive access to experts for tailored recommendations on:
-
Revolutionizing manufacturing with AI-powered data insights
-
Building resilient and intelligent supply chain ecosystems
-
Automating factory operations with cloud-driven efficiency
-
Scaling SAP and enterprise systems for next-gen manufacturing
Are you ready to make your move? We can connect you to the right experts.